{
  "id": "54e221f6ae9738404b000010",
  "type": "summary",
  "question": "Describe the mechanism of action of aliskiren. ",
  "ideal_answer": "Aliskiren is a low-molecular-weight, orally active, hydrophilic non-peptide molecule that blocks renin and consequential angiotensin I generation. Renin inhibition interrupts the renin-angiotensin-aldosterone system (RAAS).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19183745",
    "http://www.ncbi.nlm.nih.gov/pubmed/19895758",
    "http://www.ncbi.nlm.nih.gov/pubmed/23355128",
    "http://www.ncbi.nlm.nih.gov/pubmed/20812878",
    "http://www.ncbi.nlm.nih.gov/pubmed/23087256",
    "http://www.ncbi.nlm.nih.gov/pubmed/20467589",
    "http://www.ncbi.nlm.nih.gov/pubmed/25534713",
    "http://www.ncbi.nlm.nih.gov/pubmed/21687346",
    "http://www.ncbi.nlm.nih.gov/pubmed/23438929",
    "http://www.ncbi.nlm.nih.gov/pubmed/23723254",
    "http://www.ncbi.nlm.nih.gov/pubmed/18374681",
    "http://www.ncbi.nlm.nih.gov/pubmed/20380486",
    "http://www.ncbi.nlm.nih.gov/pubmed/21285669",
    "http://www.ncbi.nlm.nih.gov/pubmed/23418282",
    "http://www.ncbi.nlm.nih.gov/pubmed/22522051",
    "http://www.ncbi.nlm.nih.gov/pubmed/19337534",
    "http://www.ncbi.nlm.nih.gov/pubmed/24003484",
    "http://www.ncbi.nlm.nih.gov/pubmed/20019471",
    "http://www.ncbi.nlm.nih.gov/pubmed/20019472",
    "http://www.ncbi.nlm.nih.gov/pubmed/19066408",
    "http://www.ncbi.nlm.nih.gov/pubmed/23764715",
    "http://www.ncbi.nlm.nih.gov/pubmed/20203685",
    "http://www.ncbi.nlm.nih.gov/pubmed/20675959",
    "http://www.ncbi.nlm.nih.gov/pubmed/18443751",
    "http://www.ncbi.nlm.nih.gov/pubmed/21779913",
    "http://www.ncbi.nlm.nih.gov/pubmed/23174623",
    "http://www.ncbi.nlm.nih.gov/pubmed/22387646",
    "http://www.ncbi.nlm.nih.gov/pubmed/19279548",
    "http://www.ncbi.nlm.nih.gov/pubmed/21628356",
    "http://www.ncbi.nlm.nih.gov/pubmed/20957132"
  ],
  "snippets": [
    {
      "text": "Preliminary assignment a direct renin inhibitor aliskiren enhances the diuretic, natriuretic and kaliyuretic effects of the drug. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24003484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren: An orally active renin inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687346",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Optimization of this compound by Novartis led to the development of aliskiren - the only direct renin inhibitor which is clinically used as an antihypertensive drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren is a direct renin inhibitor that interrupts the renin-angiotensin-aldosterone system (RAAS) at its rate-limiting step.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21285669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THE READER WILL GAIN: Aliskiren, the first approved renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic non-peptide molecule that blocks angiotensin I generation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAKE HOME MESSAGE: The DRI aliskiren is an effective antihypertensive agent that preliminary data suggests has a beneficial effect in CVD and CKD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20380486",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren is a novel molecule which blocks the renin-angiotensin-aldosterone system in its rate limiting step by renin inhibition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019472",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After discovery of the first direct renin inhibitor, aliskiren, which blocks the renin-angiotensin-aldosterone system in the first rate limiting step, in addition to angiotensin-converting enzymes (ACE) and angiotensin-receptor blockers (ARB), renin has become an important target nowadays. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019471",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren, the first orally effective direct renin inhibitor, is an effective antihypertensive agent with distinctive properties including placebo-like tolerability, pharmacologic effects that persist after drug discontinuation, and a unique mechanism of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren, the first direct renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic nonpeptide. Aliskiren blocks Ang I generation, while plasma renin concentration increases because the drugs blocks the negative feed-back exerted by Ang II on renin synthesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19183745",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19066408",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "One drug that emerged from this effort is aliskiren, a direct human renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I (Ang I).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19066408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With its unique mechanism of action, combining aliskiren with another RAAS-blocking agent that has a different mechanism of action may provide more comprehensive blockade of the RAAS, potentially conferring additional clinical benefits.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21285669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the ALTITUDE trial the use of the direct renin inhibitor, aliskiren, was associated with hypotensive episodes and an excess of ischaemic stroke",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Renin is the rate limiting enzyme of the RAAS and aliskiren is a highly potent and selective inhibitor of the human renin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534713",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aliskiren, the first direct renin inhibitor to be approved for the treatment of hypertension, blocks the RAAS at its point of activation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20203685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With its unique mechanism of action, combining aliskiren with another RAAS-blocking agent that has a different mechanism of action may provide more comprehensive blockade of the RAAS, potentially conferring additional clinical benefits",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21285669",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#4240636"
  ]
}